Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed with results

Key Signals

2 with results89% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (5)
P 1 (1)
P 2 (9)
P 3 (3)

Trial Status

Unknown10
Completed8
Recruiting3
Active Not Recruiting2
Enrolling By Invitation1
Terminated1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT07222800Phase 3RecruitingPrimary

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT03037385Phase 1Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT05551052Active Not Recruiting

CRC Detection Reliable Assessment With Blood

NCT04744688Completed

Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment

NCT04755920Phase 2Recruiting

SGM-101 in Colorectal Brain Metastases.

NCT06260150Not ApplicableActive Not Recruiting

Application of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients.

NCT03559543Phase 2Completed

Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

NCT06048146Not ApplicableEnrolling By Invitation

A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis

NCT04644315Phase 2Terminated

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT04949282Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04080843Phase 2Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

NCT05322486Unknown

Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases

NCT04673136Not ApplicableCompleted

Usefulness of GI-GENIUS in FIT-based Colorectal Cancer Screening Program.

NCT05193292Phase 2Unknown

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

NCT03659357UnknownPrimary

Study of Small Bowel Tumor With Dual-phase Enhanced Computed Tomography (CTE) and Magnetic Resonance Enterography (MRE)

NCT02785783Not ApplicableCompleted

Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection

NCT03271255Phase 2Unknown

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

NCT01996306Phase 3Completed

A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC

NCT02005965Unknown

Low Rectal Cancer Study (MERCURY II)

NCT01037049Phase 2Unknown

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Scroll to load more

Research Network

Activity Timeline